| Prev Close | 526.53 |
| Day Low/High | 500.25 / 519.65 |
| 52 Wk Low/High | 325.35 / 543.55 |
| Avg Volume | 994.60K |
| Exchange | NASDAQ |
| Shares Outstanding | 106.29M |
| Market Cap | 55.97B |
| EPS | 6.20 |
| P/E Ratio | 63.67 |
| Div & Yield | N.A. (N.A) |
Latest News
Biotech Movers: Regeneron Slides Back After Big Gains
The main headwind for Regeneron is that Swiss pharma giant Novartis could soon be a rival to the eye drug that drives most of Regeneron's revenue.
Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day
Healthcare leads markets after the release of the Senate health plan.
Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill
Healthcare leads markets after the release of the Senate health plan.
Healthcare Leads as Stocks Turn Higher After Release of Senate Bill
Healthcare leads markets after Senate bill's release.
Bitter Battle Between Growth and Value: Cramer's 'Mad Money' Recap (Wednesday 6/21/17)
Growth is crushing value, says Jim Cramer, and the dynamic is more pronounced in individual sectors.
Regeneron Soars After Eye Drug Competitor Novartis Releases Positive Data
Novartis released data from its RTH258 clinical trials illustrating that RTH258 does not need to be injected as often as Regeneron's rival drug, Eylea.
9 Incredible Jobs That Let You Travel For Free
Traveling can be a life-changing event, but it's often costly.
Inovio Pharmaceuticals: Cramer's Top Takeaways
Jim Cramer takes a closer look at Inovio Pharmaceuticals, a small biotech developing DNA-based immunotherapies to treat cancer.
Stay Focused, People!: Cramer's 'Mad Money' Recap (Thursday, 6/8/17)
Jim Cramer says the story is less about Comey vs. Trump than it is about Nvidia vs. Nordstrom.
Amgen Wants to Boost Label on Powerhouse Repatha
The day before Amgen appeared in court, the biopharma giant announced a submission to change its label on powerhouse drug Repatha.
Lululemon Makes for Luluwavering; Rally Earns Some Trust: Jim Cramer's Best Blog
Jim Cramer discusses Lululemon and also mentions that the rally is earning some trust.
Alexion Pharma: Negative Market Sentiment Creates Buying Opportunity
I think the market is obsessing over the Alexion negatives and not looking at the real potential for positive catalysts ahead.
The New #233 Most Shorted S&P 500 Component: Regeneron Pharmaceuticals
The most recent short interest data has been released for the 04/28/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Allergan Must Show Mergers, Drug Pipeline Can Make Up For Lost Sales
Analysts estimate total revenue will fall 6.9% to $3.53 billion in the quarter due to the loss of patent exclusivity on some drugs and divestitures of major business lines.
Biotech Movers: Horizon, OncoMed, Inovio
Horizon Pharma, OncoMed Pharmaceuticals and Inovio Pharmaceuticals were among the biotech stock movers in early trading on Monday.
Oil Slide Puts Market Into Rotation: Cramer's 'Mad Money' Recap (Thursday 5/4/17)
Gyrations hit market, as traders drop oil, buy safety.
Regeneron Shares Rise After Reporting Better-Than-Expected Sales
The Tarrytown, N.Y.-based biopharmaceutical firm had first-quarter revenue of $1.32 billion.
Wingstop, Sanofi, Micron Technology: 'Mad Money' Lightning Round
Jim Cramer is bullish on Wingstop, Sanofi, Micron Technology and Nisource.
Sanofi And Regeneron Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent® (alirocumab) Injection
- Monthly dosing schedule now approved in both United States and European Union -
